Cell Therapy Platform Dev With Precigen CEO Dr. Helen Sabzevari
Source: Bioprocess Online

Learn how Precigen is advancing a deep pipeline of immuno-oncology, infectious disease, and autoimmune disorder candidates through the clinic on the back of its UltraCAR-T platform. CEO Dr. Helen Sabzevari describes the promise of the platform to change the CAR T complexity paradigm with an overnight manufacturing process to affect patients in urgent need of timely therapy.
        access the Podcast!
        
            Log In
        
    
    
    
    Get unlimited access to:
            Trend and Thought Leadership Articles
            
        
        
            Case Studies & White Papers
            
        
        
            Extensive Product Database
            
        
        
            Members-Only Premium Content
            
        
    
        Welcome Back! Please Log In to Continue.
        
            X
        
    
    Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
        Subscribe to Bioprocess Online
        X
    
    
        Subscribe to Bioprocess Online
    
    
                

